Giant cell myocarditis after first dose of BNT162b2 – a case report

Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, Valentin G., Schallhorn, Sven, Zwadlo, Carolin, Diekmann, Johanna, Länger, Florian, Jonigk, Danny David, Kempf, Tibor, Schultheiss, Heinz‐Peter, Bauersachs, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350328/
https://www.ncbi.nlm.nih.gov/pubmed/35733299
http://dx.doi.org/10.1002/ejhf.2590
_version_ 1784762202356449280
author Hirsch, Valentin G.
Schallhorn, Sven
Zwadlo, Carolin
Diekmann, Johanna
Länger, Florian
Jonigk, Danny David
Kempf, Tibor
Schultheiss, Heinz‐Peter
Bauersachs, Johann
author_facet Hirsch, Valentin G.
Schallhorn, Sven
Zwadlo, Carolin
Diekmann, Johanna
Länger, Florian
Jonigk, Danny David
Kempf, Tibor
Schultheiss, Heinz‐Peter
Bauersachs, Johann
author_sort Hirsch, Valentin G.
collection PubMed
description Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work‐up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.
format Online
Article
Text
id pubmed-9350328
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Ltd.
record_format MEDLINE/PubMed
spelling pubmed-93503282022-08-04 Giant cell myocarditis after first dose of BNT162b2 – a case report Hirsch, Valentin G. Schallhorn, Sven Zwadlo, Carolin Diekmann, Johanna Länger, Florian Jonigk, Danny David Kempf, Tibor Schultheiss, Heinz‐Peter Bauersachs, Johann Eur J Heart Fail Case Report Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work‐up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations. John Wiley & Sons, Ltd. 2022-07-11 2022-07 /pmc/articles/PMC9350328/ /pubmed/35733299 http://dx.doi.org/10.1002/ejhf.2590 Text en © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Hirsch, Valentin G.
Schallhorn, Sven
Zwadlo, Carolin
Diekmann, Johanna
Länger, Florian
Jonigk, Danny David
Kempf, Tibor
Schultheiss, Heinz‐Peter
Bauersachs, Johann
Giant cell myocarditis after first dose of BNT162b2 – a case report
title Giant cell myocarditis after first dose of BNT162b2 – a case report
title_full Giant cell myocarditis after first dose of BNT162b2 – a case report
title_fullStr Giant cell myocarditis after first dose of BNT162b2 – a case report
title_full_unstemmed Giant cell myocarditis after first dose of BNT162b2 – a case report
title_short Giant cell myocarditis after first dose of BNT162b2 – a case report
title_sort giant cell myocarditis after first dose of bnt162b2 – a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350328/
https://www.ncbi.nlm.nih.gov/pubmed/35733299
http://dx.doi.org/10.1002/ejhf.2590
work_keys_str_mv AT hirschvalenting giantcellmyocarditisafterfirstdoseofbnt162b2acasereport
AT schallhornsven giantcellmyocarditisafterfirstdoseofbnt162b2acasereport
AT zwadlocarolin giantcellmyocarditisafterfirstdoseofbnt162b2acasereport
AT diekmannjohanna giantcellmyocarditisafterfirstdoseofbnt162b2acasereport
AT langerflorian giantcellmyocarditisafterfirstdoseofbnt162b2acasereport
AT jonigkdannydavid giantcellmyocarditisafterfirstdoseofbnt162b2acasereport
AT kempftibor giantcellmyocarditisafterfirstdoseofbnt162b2acasereport
AT schultheissheinzpeter giantcellmyocarditisafterfirstdoseofbnt162b2acasereport
AT bauersachsjohann giantcellmyocarditisafterfirstdoseofbnt162b2acasereport

Ejemplares similares